HCL-TECHNOLOGIES
27.2.2020 17:17:12 CET | Business Wire | Press release
HCL Foundation (HCLF), the Corporate Social Responsibility (CSR) arm of HCL Technologies, today announced the recipients of the fifth edition of HCL Grant in the presence of Padma Bhushan, Mr. Kapil Dev, a legend in the global world of cricket and former captain of the Indian Cricket team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200227005709/en/
HCL Grant is one of the biggest and most coveted institutionalized CSR grants in India that aims to recognize the rise of the Fifth Estate - the Non-Governmental Organizations (NGOs).
The evening was also graced by Mr. Shiv Nadar, Founder & Chairman, HCL, Ms. Roshni Nadar Malhotra, Vice Chairperson of HCL Technologies and the Chairperson of its CSR committee, and Mr. Prateek Aggarwal, Chief Financial Officer, HCL Technologies along with senior dignitaries, officials, NGO-partners and HCL leadership.
HCL Grant 2020 witnessed three NGOs across the categories of Education, Healthcare and Environment receiving a grant of ₹5 crores each. The remaining six finalists across the three categories also received ₹25 lakhs each, taking the overall Grant to ₹16.5 crore.
The finalists and the winners were selected by an eminent jury, which was chaired by Ms. Robin Abrams, Member of the Board, HCL Technologies.
Recipients of HCL Grant 2020:
-
Environment- The 2020 HCL Grant winner in this category is Under The Mango Tree Society.
Project Location: 4 districts (Gujarat, Maharashtra and Madhya Pradesh) -
Healthcare- The 2020 HCL Grant winner in this category is Operation ASHA.
Project Location: Kullu (Himachal Pradesh) -
Education- The 2020 HCL Grant winner in this category is Bal Raksha Bharat.
Project Location: Leh (Ladakh) and Budgam (J&K)
“It is extremely important to bring equal opportunities to people coming from every strata of the society. Health, Education and Environment are one of the most important pillars towards India’s development goals and I am highly impressed with the kind of impact these NGOs are bringing in the rural communities. Also, the robustness of the identification process is something I have not witnessed before. I congratulate both HCL as well the winners and finalists for the phenomenal work they are doing in their respective fields,” Mr. Kapil Dev said while addressing the audience at the event.
Excluding the current grant, HCL Grant has already disbursed ₹51.5 crores (US$ 7.4Mn) to benefit nearly 500,000 people and its supported projects aim to cover over a million people spread across 7,500 villages across 13 States and one Union Territory in the country.
“HCL Foundation is our long-term commitment for social development and today it has improved over 1.5 million lives across our country. Our collaborative model allows us to support communities with critical concerns needing immediate attention and HCL Grant is a prime example of the same. I am proud to say that today the improvements we have been able to drive together with the HCL Grant partner NGOs is not just in terms of immediate impact on beneficiary lives, but also about ensuring long-term sustainable change by influencing state and government policies,” said Ms. Roshni Nadar Malhotra, Vice-Chairperson, HCL Technologies and Chairperson, CSR Committee, HCL Technologies.
Ms. Nidhi Pundhir, Director HCL Foundation, said, “This is a very special year for us as we complete half a decade of empowering the NGOs that are committed to ushering change. This annual HCL Grant event is a culmination of our year-long efforts to identify partners who have the potential to achieve the maximum impact through their social development projects.. We are truly honored to have received applications from all parts of the country and my heartiest congratulations to the winning NGOs for giving us the opportunity to partner with them and support ideas for impactful positive change.”
HCL Foundation also released the compendium of the previous year’s finalists and winning NGOs, named “Fifth Estate – NGOs Transforming Rural India in Environment, Health and Education”.
For more information please visit www.hclfoundation.org/hcl-grant .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005709/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
